Study results show that the AdaptivCRT algorithm is associated with improved patient survival. The real-world, prospective registry of 1,835 patients, use of the AdaptivCRT algorithm was associated with a 31% relative reduction in all-cause mortality compared to conventional cardiac resynchronisation therapy (CRT) (p=0.02).
Medtronic’s AdaptivCRT algorithm personalises therapy, adjusting how the implanted CRT device paces the heart according to minute-to-minute evaluations of each patient’s rhythm, and is being assessed for superiority over conventional CRT in a randomised clinical trial, AdaptResponse. The data were recently presented at Heart Rhythm 2018 (HRS; 9–12 May, Boston, USA).
“Heart failure patients typically have several other medical conditions and are at risk for frequent hospitalisations and even death,” said Jagmeet P Singh, associate chief of the Cardiology Division of Massachusetts General Hospital in Boston, USA. “The AdaptivCRT algorithm is not only linked to improved patient survival, but it also has previously been shown to reduce the risk of atrial fibrillation and hospital readmissions.”
Atrial fibrillation (AF), an irregular quivering or rapid rhythm in the heart’s upper chambers, is one of the most common heart rhythm disorders, and a large percentage of heart failure patients also have AF. Prior analyses of AdaptivCRT have shown a 46% reduction in episodes of AF lasting more than 48 hours, compared to patients treated with conventional CRT.
Additionally, AdaptivCRT allows physicians to tailor CRT to the individual needs of each patient, which has been shown to translate into a 59% reduction in a patient’s odds of a 30-day heart failure readmission. Evidence from the Adaptive CRT randomised clinical trial further demonstrated that AdaptivCRT increases CRT response rate, reduces unnecessary right ventricular pacing, and improves clinical outcomes for patients with normal AV conduction.